RxDoctor Payments Data

Sonia Sood, MD

Family Medicine · Webster, TXNPI 1699747592

Payments from drug & device makers

$890in general payments, 2019–2025

Across 50 payments — averaging $17.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amarin Pharma, Inc.$213
  • Pfizer$139
  • Inspire Medical Systems, Inc.$102
  • Exact Sciences$87
  • Medtronic$58
  • Novo Nordisk$55
  • plus $235 from 11 others

What the payments were for

  • Food & beverage$83193%
  • Education$597%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$890 in reported general payments places this provider in the 60th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$49,196
Medicare patients
183
Services billed
619

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide16$14,609
EliquisApixaban11$11,325
Trelegy ElliptaFluticasone/Umeclidin/Vilanter14$9,264
SymbicortBudesonide/Formoterol Fumarate30$7,624
Atorvastatin Calcium338$2,921
Levothyroxine Sodium168$1,678
Gabapentin100$1,661
Rosuvastatin Calcium93$1,376
Omeprazole106$1,344
Albuterol Sulfate HfaAlbuterol Sulfate60$1,276
Fluticasone Propionate59$1,052
Amlodipine Besylate181$971
Losartan Potassium103$926
Nifedipine ErNifedipine12$860
Metoprolol Succinate63$816

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$55$14,60916 claims
PfizerEliquis$139$11,32511 claims
GSKTrelegy Ellipta$13$9,26414 claims
AstraZenecaSymbicort$13$7,62430 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Webster

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →